Corporate Profile

Unum Therapeutics is a biopharmaceutical company focused on developing curative cell therapies to treat patients with advanced cancers. Unum’s novel proprietary technology called Bolt-On Chimeric Receptor (BOXR) is designed to improve the functionality of engineered T cells by discovering and incorporating a “bolt-on” transgene into a patients’ engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Unum’s BOXR1030, the first preclinical product candidate to emerge from the BOXR platform, is composed of a GPC3-targeted CAR T cell and a “bolt-on” enzyme called glutamic-oxaloacetic transaminase 2 (GOT2) that aims to improve T cell function in the solid tumor microenvironment through enhanced metabolism. GOT2 plays a central metabolic role by linking multiple pathways involved in biosynthesis and cellular energy production.

News Releases